Solid Lipid Nanoparticles for Efficient Oral Delivery of Tyrosine Kinase Inhibitors: A Nano Targeted Cancer Drug Delivery

Sukanta Satapathy, Chandra Sekhar Patro

Centurion University of Technology and Management, Odisha, India.

Abstract
Tyrosine kinase inhibitors (TKIs) are used as targeted therapy for cancer by inhibiting the signaling pathway and tumor growth. Many TKIs got approved by FDA in recent times for the treatment of cancer by oral route. However, the TKIs have formulation challenges leading to compromised bioavailability which can cause a weak therapeutic response. The cancer nanotherapeutics using nanocarriers based drug delivery has emerged as an advanced tool to provide a solution to formulation challenges and a better cancer therapy by overcoming the limitations in conventional cancer therapy. This review describes the various formulation issues of anticancer drugs with a special reference to TKIs, as well as the capability of solid lipid nanoparticles (SLNs) for an efficient nano targeted cancer drug delivery.

Introduction
Cancer is a deadly disease posing a global threat to 185 countries with 19.2 million new cases and 9.9 million deaths reported in 2020. GLOBOCAN 2020, supported by the International Agency for Research on Cancer, WHO, estimates cancer incidences and death for 36 types of cancers in 185 countries. This data is available in Global Cancer Observatory, an online web-based database. The future statistics revealed the possibility of a sharp rise of cancer new cases from 19.2 million in 2020 to 30.2 million in 2040. The treatment options available for cancer are surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, hormone therapy, stem cell transplant, and precision medicine. The conventional chemotherapy drugs suffer from constraints such as, lack of bioavailability and poor aqueous solubility, tissue toxicity due to nonspecific biodistribution, lack of targeted drug action, instability in circulation, drug resistance, and limited cellular uptake. These limitations led to the lesser cytotoxic activity of anticancer drugs and ultimate suboptimal therapeutic efficacy and patient cure. Targeted cancer therapies involve the blocking of the molecular targets with anticancer drugs specifically inhibiting the molecular target and thus, the growth and metastasis of the cancer are stopped. Targeted cancer therapy can solve the limitations of conventional chemotherapy, such as, nonspecific biodistribution and cell targeting. The various targeted therapies use small molecular drugs, monoclonal antibodies and signal transduction inhibitors. The tyrosine kinase inhibitors (TKIs) are nano-materials used to stop cell signaling by inhibiting signal transduction pathway. It has created a new hope in cancer treatment in the current age. However, the various formulation challenges of TKIs are to be addressed by formulation scientists to improve the efficacy of the existing drugs. The cancer nanotherapeutics using nanocarriers for drug delivery has emerged as an advanced tool to address the formulation challenges and better cancer therapy. The strategy can meet the limitations in the conventional cancer therapy with superior active and passive drug targeting. The nanocarriers such as, polymeric nanoparticles, micelles, dendrimers, liposomes, solid lipid nanoparticles (SLNs), nanotubes, loaded with chemotherapeutic drugs can be developed to improve the limitations of conventional anticancer treatment and develop highly capable anticancer drugs in terms of therapeutic activity and functionality. The various limitations of liposomes are limited drug loading capacity, drug leakage and vascular instability. On the other hand, the limitations of polymeric nanoparticles are nonavailability of large-scale production methods, polymer cost, cell toxicity of polymeric material, and toxic solvent residue. Presently, the lipid-based nanocarriers (SLNs etc) have drawn attention of researchers to deliver the active agents to the desired target with many advantages over the limitations of other nanocarriers. These solid lipid nanocarriers are also capable to address the formulation challenges associated with the TKIs to improve their bioavailability. Many researchers found that TKIs can be formulated into various nano-carrier-based drug delivery to improve their anticancer capacity.

*Corresponding Author: Sukanta Satapathy, Tel: 6304595441, Email: sukanta.satapathy@cutm.ac.in

© 2022 The Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers.
This review summarized the SLN formulation approach for delivery of the TKIs with enhanced anticancer potential.

**Tyrosine kinase inhibitors**

Tyrosine kinase is the enzyme that helps in the phosphorylation of proteins and activates a signal transduction pathway leading to cell growth, differentiation, apoptosis and angiogenesis in a normal cell. Mutation in these tyrosine kinases leads to defective signal transduction and ultimately causes tumor growth.\(^\text{11}\) Tyrosine kinases can be classified as receptor protein kinases, which involve the transduction of extracellular signals into active intracellular signal transduction proteins, and nonreceptor protein kinases, which are involved in the transduction of signals within the cell.\(^\text{12}\) Receptor tyrosine kinases, such as epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) are involved in cancer proliferation and angiogenesis. Thus, inhibition of these receptors can stop the signaling pathways and ultimately inhibit the cancer growth and proliferation.\(^\text{13}\) The TKIs are used as a targeted cancer therapy, by inhibiting the signaling pathway and tumor growth. Many TKIs are approved by the FDA for cancer treatment. The updated list can be found at [https://www.icoa.fr/pkidb/].\(^\text{14}\) Oral administration of chemotherapy has more advantages over the parenteral route. The major advantages are greater patient convenience and the flexibility of drug exposure.\(^\text{15}\) The bioavailability of the TKIs which are administered orally, is dependent on various gastrointestinal factors such as absorption and first-pass metabolism.\(^\text{11}\) Thus, their bioavailability is a major issue for an optimized formulation. The various factors that affect the bioavailability of TKIs are discussed to have a better approach to deal with the formulation issues, which can provide an efficient cancer therapy.

**Formulation issues of TKIs**

The formulation of TKIs is a major challenge due to variable bioavailability. The various issues of formulation are discussed in the following sections.

**Poor oral bioavailability of TKIs**

The small molecule TKIs (smTKIs) are used orally for targeted drug delivery in cancer chemotherapy. However, highly variable pharmacokinetics is observed with the smTKIs, which ultimately leads to poor oral bioavailability.\(^\text{16}\) Bioavailability is determine by the rate and extent of drug absorbed into the systemic circulation. The poor and variable bioavailability of smTKIs may result in variable plasma level, which can lead to decreased therapeutic response.\(^\text{7}\) Table 1 presents the BCS classification of different TKIs. Various factors, either single or in combination are responsible for the poor bioavailability of the TKIs. The physicochemical, biological and other factors that influence the bioavailability of smTKIs are discussed.\(^\text{17}\) The bioavailability of various TKIs are given in the Table 2.\(^\text{18,19}\) Apart from variable bioavailability, the inter individual variation in pharmacokinetics can affect the dose response, either overdose or underdose, leading to toxicity or development of resistant clones.\(^\text{16}\) Therapeutic drug monitoring is an essential approach for TKIs for dose adjustment to have a better response and reduced side effect due to fixed dose for every individual.\(^\text{11,20}\) The interplay of various factors, for a poor and variable bioavailability are discussed below.

Factors affecting bioavailability of TKIs are:

- **Physicochemical factors:** Drug aqueous solubility and dissolution, drug degradation and stability in the gastrointestinal tract, lipophilicity of the drug, size of the drug molecule.
- **Food and drug interaction factors:** Food effect, drug interaction with acid reducing agents.
- **Biological barriers /Physiological factors:** Trans membrane efflux of the drugs (P-gp efflux pump), first pass metabolism (intestinal and liver cytochrome P450 metabolic enzymes).

**Physicochemical factors**

**Drug solubility and dissolution**

The solubility enhancement is essential for BCS class II drugs. The bioavailability of these classes of drugs are solubility/dissolution rate limited, but not limited by the permeability rate.\(^\text{21}\) The BCS (Biopharmaceutics classification system) class is assigned to the drugs as per their water solubility and GI membrane permeability characteristics.\(^\text{22}\) The assigned BCS class data are taken from the FDA clinical pharmacology, biopharmaceutics review documents and the published reviews.\(^\text{23,24}\) The various BCS classes assigned to different TKIs are represented in Table 1. The increase in Bioavailability of BCS class II drugs can be achieved by enhancing the dissolution.\(^\text{21}\) The TKIs exhibit poor solubility (listed in the Table 2) and thus, there is a need for solubility enhancement to have good oral bioavailability. The TKIs are given orally. Dissolution is the initial step for oral absorption. The GI fluid solubility of the drug is necessary for the oral absorption of drugs. The TKIs are weakly basic and they show pH-dependent aqueous solubility.

---

**Table 1. BCS classification of some tyrosine kinase inhibitors**

| BCS Class | Solubility | Permeability | TKIs |
|-----------|------------|--------------|------|
| I         | High       | High         | Afatinib, Carboxazindib, Dabrafenib, Dasatinib, Erlotinib, Gefitinib, Lapatinib, Pazopanib, Regorafenib, Vandetanib |
| II        | Low        | High         | Bosutinib, Crizotinib, Nilotinib, Sunitinib, Vemurafenib |
| III       | High       | Low          | Afatinib |
| IV        | Low        | Low          |      |
GI pH is an important factor that affects absorption and bioavailability. The GI pH profile includes stomach with a highly acidic pH 2, Jejunum with slightly acidic pH 5-6, and Ileum with slightly alkaline pH 7-8. The TKIs are absorbed mostly from the small intestine which has a larger surface area due to the epithelial folding and villous structure. The drug solubility of TKIs in the small intestine is needed for absorption. The small intestine transit time for the drugs is observed to be 3-4 hours and the value does not change with the presence of food. The TKIs are weak bases; hence, upon oral administration when they reach stomach and due to acidic pH in the stomach they get ionized. As a result, the drug solubility increases in the stomach, but in the intestine, due to the increase in pH, the solubility decreases. Many of the TKIs show the pH dependent solubility.

### Table 2. Physicochemical properties and bioavailability of some TKIs

| Name of TKIs | MW* (Da) | Bioavailability (%) | Solubility mg/mL | log p | Primary target | IC50 in nM |
|--------------|----------|---------------------|------------------|------|---------------|-----------|
| Afatinib     | 486      | -                   | 0.0128           | 3.77 | ErbB1/2/4     | 10,14,1   |
| Alectinib    | 483      | 37                  | 0.0105           | 5.59 | ALK, RET      | 1.9       |
| Avapritinib  | 499      | -                   | 0.0301           | 2.68 | PDGFR         | 0.5       |
| Axitinib     | 386      | 58                  | 0.000551         | 4.17 | VEGFR1/2/3    | 0.1,0,2,01-0.3 |
| Brigatinib   | 584      | -                   | 0.022            | 5.11 | ALK           | 0.6       |
| Cabozantinib | 501      | -                   | 0.00199          | 4.01 | VEGFR2, RET   | 0.035,4   |
| Capmatinib   | 412      | -                   | 0.00529          | 3.04 | c-MET         | 0.13      |
| Ceritinib    | 558      | 25                  | 0.00222          | 5.23 | ALK           | 0.2       |
| Crizotinib   | 450      | 43                  | 0.00611          | 3.82 | ALK, ROS1     | 24,<0.025 |
| Daclomitinib | 470      | 80                  | 0.00874          | 4.88 | EGFR          | 6         |
| Entrectinib  | 561      | -                   | 0.0089           | 5.03 | TRKA/B/C, ROS1 | 0.1 to 1.7 |
| Erlotinib    | 446      | -                   | 0.013            | 3.57 | FGFR1/2/3/4   | ----      |
| Erlotinib    | 393      | 60                  | 0.00891          | 3.13 | EGFR          | 2         |
| Fostamatinib | 580      | 55                  | 0.052            | 2.78 | Syk           | 41        |
| Gefitinib    | 447      | 60                  | 0.027            | 4.02 | EGFR          | 26        |
| Gilatentinib | 552      | -                   | 0.0223           | 3.51 | Flt3          | 0.29      |
| Lapatinib    | 580      | <25                 | 0.0223           | 5.18 | ErbB1/2/HER2  | 10.8,9,2  |
| Larectrinib  | 428      | 34                  | 0.238            | 2.07 | TRKA/B/C      | ----      |
| Lenvatinib   | 427      | -                   | 0.00622          | 3.03 | VEGFR1, RET   | 22        |
| Lorlatinib   | 406      | 81                  | 0.108            | 2.01 | ALK           | --        |
| Midostaurin  | 571      | -                   | 0.0157           | 4.52 | Flt3          | 912(FLT1) |
| Neratinib    | 557      | -                   | 0.00674          | 4.72 | ErbB2/HER2    | 59        |
| Nintedanib   | 540      | 5                   | 0.0309           | 3.7  | FGFR1/2/3     | 69,37,108 |
| Osimertinib  | 500      | -                   | 0.0224           | 4.47 | EGFR T970M    | 11.44     |
| Pazopanib    | 438      | 14-39               | 0.0433           | 3.59 | VEGFR1/2/3    | 10,30,47  |
| Pemigatinib  | 487      | -                   | 0.144            | 2.26 | VEGFR1/2/3/4  | 0.4,0,5,1,2,30 |
| Pexidartinib | 417      | -                   | 0.00315          | 4.64 | CSF1R         | 20        |
| Pralsetinib  | 534      | -                   | 0.0101           | 3.63 | RET           | 0.3       |
| Regorafenib  | 483      | 69-83               | 0.00102          | 4.53 | VEGFR1/2/3    | 13,4,2,46 |
| Ripretinib   | 510      | -                   | 0.00583          | 4.3  | KIT/PDGFR     | 4         |
| Selpercatinib| 526      | 73                  | 0.0299           | 3.03 | RET           | 1         |
| Sorafenib    | 465      | -                   | 0.00171          | 4.12 | VEGFR1/2/3    | 15,90,20  |
| Sunitinib    | 398      | -                   | 0.0308           | 3.24 | VEGFR2        | 80        |
| Tucatinib    | 481      | -                   | 0.004            | 3.87 | ErbB2/HER2    | 8,7       |
| Upadacitinib | 380      | -                   | 0.0707           | 2.57 | PDGFR         | -         |
| Vandetanib   | 475      | -                   | 0.0102           | 5.01 | VEGFR2        | 40        |

Abbreviations: EGFR (epidermal growth factor receptor), HER (human epidermal growth factor receptor), PDGFR (platelet derived growth factor receptor), VEGFR (vascular endothelial growth factor receptor), FGFR (fibroblast growth factor receptor), RET (rearranged during transfection), ALK (anaplastic lymphoma kinase), CSF (colony stimulating factor).

*Data taken from NIH PubChem. \(^2\)Available data from registration documents by FDA. \(^3\)Data taken from Drug Bank. \(^4\)Data taken from Blue ridge institute for medical research. \(^5\)Data taken from selleckchem.
design of a good formulation.

**Drug degradation and stability in the GI tract**

The stability of drugs is affected by acidic pH and ultimately affects absorption and bioavailability. The chemical stability of a drug in the GI tract is affected by the pH. The anticancer drug etoposide and chlorambucil show poor chemical stability in GI fluids leading to variable and low bioavailability. The SLNs provide matrix encapsulation of the drug which leads to protection from acid instability and also helps in sustained release. Drug metabolism by hydrolysis in GIT and plasma is also protected by the SLN carrier drug delivery. Thus, the TKIs can provide significant advantages in the SLN formulation.

**Lipophilicity of the drug**

Lipophilicity determines the passive permeability of the drug. The log P values (representing the partition of the drug between octanol and aqueous buffer at a pH of 7.4 as a measure of lipid solubility) are the measure of lipophilicity. If the logP value is below –0.4, the compound faces difficulty to cross the GI barrier. However, this will be facilitated if the log P value is above 5. The uncharged fraction of the drugs can cross the GI membrane while the charged fraction cannot. For weak acids and bases (weak base like TKIs) the pka values are considered for the permeable membrane because the pka represents that value of pH at which 50% of the drug is in ionized form and 50% of drug exists in the unionized form. Lipinski’s rule of five specifies states that the partition coefficient should not be more than five and the values in the range 1-3 show good absorption and values of log p <1 and > 3 show poor penetration. Partition coefficients of the drugs in the range of 1–3 show good passive absorption across intestinal barriers and log P values outside the limit (1 and 3) have poor transportation characteristics. The log p values of the various TKIs are given in Table 2. The lipophilicity of TKI is an important parameter that affects bioavailability.

**Size of drug and bioavailability**

The high molecular weight of the drugs can cause difficulty to cross the GI membrane by passive diffusion. The molecular weight, lipophilicity and surface polarity determine the membrane permeation of the drug. Lipinski rule also states that the molecular weight, if greater than 500 Da, leads to large size of the molecule, hampers passive absorption due to concentration gradient, and leads to low bioavailability due to the slow absorption. The molecular weights of various TKIs are given in Table 2. The size of the TKIs affects bioavailability.

**Food and drug interaction factors**

**Food effect with TKIs**

The interaction of food with the administered drug also affects bioavailability. The buffering effect, dilutant effect of food, the composition of GI fluid during feed state resulting in the change in pH of the gastric environment, and change in solubility of drugs lead to less dissolution. Food can affect gastric emptying rate. Change in residence time, modulate efflux transporter and metabolizing enzymes can also affect the absorption of drugs and bioavailability. The TKIs are oral targeted drugs with positive food effects, which means the administration of TKIs with food increases the absorption. The TKIs taken with food may cause toxicity due to increased concentration of anticancer drugs. Hence these drugs are not taken with food. These drugs are taken before 2 hours or after one hour of taking food. Lipid formulations such as, SLNs resemble the high fat content of a meal which increases solubilization of the administered drug molecule. TKIs show the variability in the absorption and bioavailability in presence of food. The grapefruit juice contains furanocoumarins (bergamottin, 67-dihydroxybergamottin) which irreversibly inhibit the intestinal metabolism, and the plasma concentration of the drugs gets increased leading to adverse effect for TKIs.

**pH regulating drugs and TKI interaction**

The TKIs are weak bases and show pH dependent solubility. The concurrent administration with acid regulating drugs like Proton pump inhibitors, antacids, and H2 receptor antagonists can raise the pH so that the solubility and absorption are affected. Hence TKIs are to be administered as per the drug interaction prescribing information. The concentration of dasatinib decreases with simultaneous administration of proton pump inhibitors or H2 antagonists due to the increase in pH and decrease in solubility of the drug, which results in the reduced efficacy of dasatinib.

**Biological barriers/Physiological factors**

**Efflux transporter proteins of GI barrier and multidrug resistance**

The physiological drug barrier is the GI membrane. The membrane transporter proteins are the molecular cause of impermeability of various anticancer drugs. The various membrane drug transporters such as, ATP binding cassette transporters (ABC transporter) like permeability-glycoprotein (P-gp), the multidrug resistance-associated proteins, and the breast cancer resistance protein (BCRP) are found to impact the absorption of anticancer drugs by acting as an efflux pump limiting the drug permeability and bioavailability for TKIs. The TKIs act as substrate or inhibitors of ABC transporters and these ABC transporters are involved in active drug efflux which can cause drug resistance for the TKIs. TKIs are taken up into the cells by the Solute carrier transporter or SLC transporters. The various organic anion transporter proteins and organic cation transporter proteins are a subfamily of SLC inhibitors and the TKIs may act as substrate or inhibitors.
for the SLC inhibitors and found to have interaction influencing the absorption of TKIs.\textsuperscript{41} The lysosomal sequestration of TKIs is also a cause of MDR in TKIs.\textsuperscript{43} All these efflux can lead to the variable bioavailability of the TKIs.

**First-pass metabolism and bioavailability**

The site for the first-pass metabolism of the drugs is the intestine and liver. The enzymes in the intestine and liver are responsible for first-pass metabolism. Cytochrome P450 (CYP) enzymes (phase I metabolism) and other conjugating enzymes (phase II metabolism) are the enzymes for the metabolism of the drugs in the liver. The enzyme CYP3A4 is the metabolizing enzyme in the intestine.\textsuperscript{43} CYP3A4 is the most important phase-1 drug-metabolizing enzyme in the body and is the mostly found as the isoform of the enzyme in the liver.\textsuperscript{46} The drugs are metabolized by the enzymes before absorption in the intestine and after absorption, the drugs enter into the enterohepatic circulation to be metabolized by the enzymes in the liver leading to the low bioavailability of drugs. The metabolized drug may act as a substrate for the Pgp and this concept of interactive action is also a highly emerging factor for interactively reducing the bioavailability.\textsuperscript{45} The role of various metabolizing enzymes such as, uridine diphospho-glucuronosyltransferases (UGTs), glutathione-S-transferases (GSTs), dihydropyrimidine dehydrogenases, and thiorpuriine methyltransferases, for creating drug resistance are also studied.\textsuperscript{46} Most of the TKIs are metabolized by CYP enzyme, CYP3A4, and also glucuronidation by UGTs,\textsuperscript{49} which may account for low bioavailability. TKIs are found to be the substrates of CYP3A4; hence, the CYP3A4 Inhibitors or inducers can change the bioavailability of the TKIs. The simultaneous use of these inhibitors or inducers with TKIs cannot be overlooked. The area under the curve of sunitinib and nilotinib increased by 11% and 29%, respectively, with grapefruit juice which is an inhibitor of CYP3A4.\textsuperscript{50} Thus, the First-pass metabolism affects the bioavailability of TKIs.

**Solid lipid nanoparticles**

SLNs are colloidal nano drug carriers with particle size ranging between 50 and 1000 nm.\textsuperscript{51} SLNs are made up of solid biodegradable lipids as a solid matrix core covered by hydrophilic surfactant.\textsuperscript{52}

**Advantages of SLNs**

The SLNs have excellent biocompatibility and low toxicity. The lipophilic drugs are better delivered by SLNs.\textsuperscript{53} The SLNs are made from physiologically compatible lipids. SLNs also show less cytotoxicity as compared to the polymeric nanoparticles.\textsuperscript{54}

Feasibility of large scale production, high product stability, biodegradability, increased entrapment efficiency, controlled drug release, drug targeting by surface modification are the advantages of SLNs over the liposomes and polymeric nanoparticles.\textsuperscript{55} SLNs also show controlled drug release by the degradation, erosion, or diffusion of the lipid matrix.\textsuperscript{53} The SLNs, can deliver the TKIs, with enhanced bioavailability and decreased resistance. Combination drug delivery with targeted therapy also possible.\textsuperscript{56} Lipid based nano carriers such as, SLNs can improve the limitations of conventional anticancer treatment by highly capable anticancer drugs in terms of therapeutic activity and functionality.\textsuperscript{53}

**Formulation of SLNs**

General formulation ingredients include solid lipid(s), emulsifier(s) with API (drugs, proteins). The other ingredients used are co-surfactants, preservatives, cryoprotectants, and charge modifiers. The lipids used are triglycerides (e.g. tristearin), partial glycerides (e.g. Imwitor), fatty acids (e.g. stearic acid), steroids (e.g. cholesterol), and waxes (e.g. cetyl palmitate). All classes of emulsifiers, which includes various surfactants (tweens), organic salts are used to stabilize the lipid dispersion.\textsuperscript{57} The detailed ingredients generally used to prepare SLNs are given in Table 3. The ingredients used to prepare TKI SLNs are specifically cited in the reference column of Table 3.

**Methods of preparation of SLNs**

The various methods of preparation of SLNs include high shear homogenization, ultrasonication or high speed homogenization,\textsuperscript{58} high pressure homogenization (cold homogenization, hot homogenization\textsuperscript{62}), microemulsion based methods, supercritical fluid method, solvent emulsification method,\textsuperscript{60} solvent evaporation method,\textsuperscript{60,61} double emulsion methods, precipitation techniques and spray drying methods.\textsuperscript{53,63} The various TKIs formulated into SLNs by using various methods are given in Table 4.

**Route of administration and Applications of SLN**

SLNs can be administered by various routes such as, oral, parenteral, nasal, topical or transdermal, ocular, rectal for various types of drugs.\textsuperscript{65,66} The SLNs find their applications in medicine, food science, cosmetics, dermaticals, and phyto pharmaceuticals nanotherapeutics for efficient delivery.\textsuperscript{62} Cancer chemotherapy finds its efficient and safe delivery by using SLNs as a nanocarrier.\textsuperscript{68} SLNs can incorporate a number of anticancer drugs and have proven to be effective in different types of tumors at breast, lung, colon, liver and brain.\textsuperscript{69} Table 5 summarizes various outcomes of TKIs through SLN delivery system.

**SLNs for efficient delivery of TKIs**

The oral delivery of TKIs is a challenge for the formulation researchers due to various formulation issues as discussed earlier. These issues can be addressed by using SLN as a carrier for drug delivery in an efficient manner.
SLNs for Efficient Oral Delivery of TKIs

SLNs are a new formulation strategy for improving the bioavailability of various poorly water-soluble drugs. SLNs were found to improve the absorption of solubility hindered drugs. The researchers use various techniques for improving the solubility of poorly water-soluble drugs include micronization, nanonization, nanoemulsion, prodrug, salt formation, co-crystallization, and solubility enhancement. SLNs are mainly used for improved oral delivery of TKIs.

### Table 3. List of ingredients used for the preparation of SLNs

| Lipids | References | Surfactants/Emulsifiers | References |
|--------|------------|-------------------------|------------|
| Triglycerides | Phospholipids | Soybean lecithin (Lipoid S 75, Lipoid S 100) | 59,60 |
| Tricaprin | | Egg lecithin (Lipoid E 80) | |
| Trilaurin | | Ethylene oxide/propylene oxide copolymers | |
| Trimyristin (Dynasan 114) | | Poloxamer 188 (PLURONIC F-68) | 59,61 |
| Tripalmitin (Dynasan 116) | | Poloxamer 407 (PLURONIC F-127) | 62,63 |
| Tristearin (Dynasan 118) | | Sorbitan ethylene oxide/propylene oxide copolymers | |
| Hydrogenated cacao-glycerides (Softisan 142) | | Poloxamer 188 (PLURONIC F-68) | |
| **Hard fat types** | | Poloxamer 407 (PLURONIC F-127) | |
| Witepsol W35 | Poloxamer 908 | |
| Witepsol H35 | Tylacapol | |
| Witepsol H42 | | |
| Witepsol E85 | | |
| **Acyl glycerols** | Bile salts | Sodium cholate | |
| Glycerol monooleate (CMS) (Imwitor 900) | 61 | Sodium glycocholate | |
| Glycerol Beheenate (Compritol 888 ATO) | 59,62 | Taurocholic acid sodium salt | |
| Glycerol palmitostearate (Precisol ATO 5) | | Taurodeoxycholic acid sodium salt | |
| **Waxes** | | | |
| Cetyl Palmitate (Crodamol CP) | Alcohol | | |
| **Fatty acids** | Butanol | | |
| Stearic acid | 60,63 | Butyric acid | |
| Palmitic acid | | Dioxyl sodium sulfosuccinate | |
| Decanoic acid | | Monooctylphosphoric acid sodium | |
| Behenic acid | | | |
| Acidan N12 (monostearate monocitrate diglyceride) | | | |

### Table 4. Method of preparation of SLNs formulation of TKIs.

| TKI (SLN formulation) | Method of preparation | Reference |
|-----------------------|-----------------------|-----------|
| Erlotinib loaded with SLN and formulated as a Dry powder inhaler. | hot homogenization method | 62 |
| Gefitinib SLNs as a dry powder inhaler | emulsion-solvent diffusion and evaporation method | 62 |
| Sorafenib SLNs for oral administration | high-speed shearing and ultrasonic treatment | 59 |
| Ceritinib SLN | Single emulsification and solvent evaporation | 61 |
| Brigatinib SLN | solvent emulsification/evaporation technique using probe-sonication. | 60 |

### Table 5. Efficient outcomes of TKIs through SLN delivery system

| TKI with SLN delivery | Outcome | Reference |
|-----------------------|---------|-----------|
| Erlotinib loaded with SLN and formulated as a dry powder inhaler | Encapsulation efficiency is 78.21%, erlotinib-SLNs show enhanced cytotoxicity. | 62 |
| Gefitinib SLNs as a dry powder inhaler | The encapsulation efficiency of 97.31 ± 0.23 %, superior anticancer effect as compared with free gefitinib. | 63 |
| Sorafenib SLNs for oral administration | Drug selectivity index value which measures the liver targeting of sorafenib-SLNs was 2.20 times higher and AUC increased by 66.7% than that of the sorafenib suspension. | 59 |
| Ceritinib | The in vitro studies indicate a maximum drug release of 95.12% in 360 min as compared to (30.12% in 360 min). Stability is more even after 90 days. | 61 |
| Brigatinib | The optimized formulation is more cytotoxic with 74.91% less dose as compared with the brigatinib suspension. Entrapment efficiency is 87.09±0.68% and drug loading is 7.86±0.44%. | 60 |
chemical modification, polymorphs, pH adjustment, solid dispersion, complexation, co-solvency, micellar solubilization, polymeric micelle, hydrotropy, self-emulsifying drug delivery system (SEDDS), liposomes, niosomes, SLNs, nanostructured lipid carriers, etc. For the TKIs which belong to class II and IV, the enhancement of bioavailability can be achieved through dissolution improvement with different strategies such as, particle size reduction, self-emulsification, cyclodextrin complexation, crystal modification, and amorphous solid dispersion. The targeted drug delivery for specific biodistribution to reduce side effects and improved therapeutic efficacy along with bioavailability improvement can be achieved by dendrimers, polymeric nanoparticles, magnetic nanoparticles, and lipid based delivery systems such as liposomes, SLNs, and nanostructured lipid carriers (NLCs). The conventional molecular optimization to improve the pharmacokinetics has been seen to be improved with nanoformulation approaches to deal with the various issues of bioavailability. The various polymeric nanocarriers, for example, polymeric nanoparticles, polymeric micelles, polymer drug conjugate, and lipid based nanocarriers are used for drug delivery through Emulsions, SEDDS, NLCs, lipid nanocapsules, layersomes, lipid drug conjugates, SLNs. They are found to be good drug delivery systems for anticancer drugs. Lipid formulations can improve solubilization, absorption, and minimize the food effect. Thus, ultimately the bioavailability of TKIs is improved.

**Nano size of SLNs to enhance the bioavailability of TKIs**

The SLNs used for the drug delivery carriers are of small size of 50-1000 nm and the absorption increases due to the increase in the surface area. This small size also favors bypassing the physiological barrier of the GI tract. In this way, the SLNs can improve the bioavailability of the small molecule TKIs.

**SLNs for reversing multidrug resistance of TKIs**

The SLNs are a better approach to reduce or reverse the multidrug resistance. The TKIs are found to inhibit the ABC transporters. A combinational strategy of treatment with other anticancer drugs can be formulated to reduce the anticancer drug resistance. However, P-gp inhibitors used to reduce drug efflux by membrane transporters, can cause complications by suppressing the immune system. Nanocarriers such as, SLNs, are found to be a better approach to by-pass the efflux pump transport. The conventional anti MDR strategy has the limitations of pharmacokinetic interaction between combination drugs of P-gp inhibitor and chemotherapeutics, suppression of immunity and physicochemical formulation issues. The novel nano drug delivery strategy can utilize SLNs which can deal with the MDR by increasing the drug uptake into tumor cells, drug accumulation in tumor cells, suppressing MDR proteins such as P-gp, increasing the bioavailability of drugs, and inducing apoptosis. The recognition of nanoparticles by P-gp is avoided with the nanoparticles and these nanoparticles accumulate in the cells, which can improve the absorption. The cytotoxicity of SLN loaded anticancer drugs such as, paclitaxel and doxorubicin was found to be increased by reversing the resistance by multi drug resistant cancer cells. The SLNs can also be formulated for TKIs to reverse the MDR of TKIs.

**SLNs for bypassing first-pass metabolism of TKIs**

The bioavailability can be improved with the simultaneous delivery of inhibitors of the ABC transporters and CYP450, however the inhibition of metabolizing enzymes may affect the bioavailability of xenobiotics and cause other side effects. The SLNs form the chylomicrons by enterocytes, thereby the lymphatic transport of lipophilic drugs is enhanced which results in bypassing the intestinal and hepatic metabolism and the bioavailability is improved. This approach can be used to increase the bioavailability of the TKIs which are the substrates for the metabolizing enzymes.

**PEGylated SLNs for efficient delivery of TKIs**

The absorption barrier of the intestinal mucosa and mucus clearance of drugs are also causes of low bioavailability. Polyethylene glycol was introduced for coating lipid-based drug carriers to have a hydrophilic layer resulting in increased oral delivery of drugs against the viscoelastic mucus layers. The PEGylated SLNs (pSLNs) are prepared to evaluate the mucus penetrating capacity and found that the pSLNs can easily penetrate the mucosal barrier as compared to the SLNs. Thus, the absorption efficiency and blood circulation time increased with an increase in relative bioavailability of 1.99 times as compared to that of the SLNs. Based on the above discussion, it can be expected that the SLNs pegylation can improve the oral bioavailability of the various TKIs, which can be a point of research in the future formulation investigation.

**SLNs for lymphatic drug uptake to improve bioavailability**

Intestinal lymphatic transport for lipids, either as food or lipophilic drug, is an alternate absorption route that opens a door for a lipid-based drug delivery system. The absorption of lipophilic drugs increases with co-administration with food of lipidic content. This concept provides the lipid based formulation approaches for drug delivery through the lymphatic route. Drugs with poor and variable oral bioavailability due to low solubility in the GI tract or pre-systemic hepatic metabolism, can be improved in terms of bioavailability by formulating into an SLN for lymphatic drug delivery with bypassing first-pass metabolism. The paracellular absorption, M cell uptake via Peyer's patches, chylomicron-assisted enterocytes absorption are the different routes of drug absorption for SLNs. The lipid core of SLNs facilitates...
lipase mediated chylomicron formation through lipid digestion and performs lymphatic uptake by lymphatic transport and lymphatic route, which can bypass hepatic first-pass drug metabolism to improve the absorption and oral bioavailability of water insoluble drugs. 

**SLN reducing drug interactions with TKIs**

The TKIs are extensively used in cancer therapy. So there is a possibility of drug interactions that may lead to additive QT prolongation and decreased TKI exposure. In oral cancer therapy, the cytotoxic effect to the GI tract is unavoidable, drug–drug interactions are observed in 46% of patients having oral cancer therapy treatment, out of which 16% were considered major interactions. This cytotoxic effect and drug interaction related side effect can be overcome with the nanoformulations.

**SLN for increasing encapsulation efficiency of TKIs**

Encapsulation efficiency and drug loading capacity are the two important parameters for the SLNs which determine the amount of drug associated with the nanoparticle or percentage of drug encapsulated into SLN, which in turn, determines the therapeutic efficacy for a drug. Erlotinib-loaded SLN based formulation of dry powder inhaler was prepared by Bakhtiary et al and it was found that the encapsulation efficiency was 78.21%. Satari et al developed glucosamine conjugated gefitinib SLNs and the optimized formulation had drug loading of 33.29%, encapsulation efficiency of 97.31 ± 0.23%. Improved anticancer effect of gefitinib loaded SLN, as compared to that of free gefitinib was studied. Thus, the SLNs can be an efficient drug carrier for TKIs to improve the encapsulation efficiency.

**IC_{50} value and enhanced cytotoxic effect of TKIs with SLNs**

The cytotoxic effect of a drug in a cancer cell is popularly studied by MTT assay, which is a cell viability test. An MTT assay is a simple and effective invitro assay for the quantification of cell viability and proliferation. A549 Lung adenocarcinoma cell line was used to see the cytotoxic potential of an anticancer drug. The drug concentration that reduces the viability of cells by 50% is termed IC_{50}. The IC_{50} value was extrapolated from the dose-response graph. Ahmed et al developed Brigatinib (BG) loaded SLNs by using solvent emulsification technique, characterized and MTT assay was performed on the optimized SLNs (BS5). It was found that the BG loaded SLN (BS5) showed better cytotoxicity against A349 lung cell lines while compared to BG suspension and blank SLN. The IC50 (µg/mL) values for blank-SLN and BS5 were found to be 89.9±2.4 and 43.85±1.8 respectively, however, IC50 for pure drug-BG was reported to be 58.53±1.3 µg/mL. Therefore, it was concluded that optimized BS5 formulation could be relatively more cytotoxic, effective in 74.91 % less dose as compared to that of the drug-suspension (BG). These values can support the fact that SLN delivery of TKIs can deliver the drugs with enhanced cytotoxic effect.

**Sustained drug release of TKIs from SLNs**

Drug release from SLNs follows the zero order diffusion controlled mechanism or erosion or degradation of the lipid matrix system of the SLN and a controlled release of the drug is obtained. An initial burst release or rapid release of drug is seen and is due to the weakly bound surface drugs on the SLN. The controlled drug release can be obtained for TKI inhibitors also. Imatinib (IMT) loaded SLNs formulations optimized with Plackett-Burman design and Box-Behnken design with variables like organic-to aqueous phase ratio, drug-to-lipid ratio, and amount of Tween™ 20 for particle size, drug loading, and encapsapsulation efficiency of IMT-SLN show the results with sustained release pattern of the drug with enhanced physicochemical characteristics. A sustained release pattern was observed with the in-vitro release profile for brigatinib. Brigatinib loaded SLNs can find an important place in the non-small cell lung cancer treatment.

**Conclusion**

TKIs are a breakthrough in cancer targeted drug delivery. The nanoformulation with SLNs is a novel cargo for the TKIs. This approach has proven to be most efficient and the results also showed promising for TKIs. The future potential for TKIs loaded SLNs will be a more efficacious discovery for formulation scientists. Future cancer therapy with the reviewed approach with SLNs and loaded TKIs will be significantly beneficial for cancer treatment.

**Conflict of Interest**

There is no conflict of interest.

**Ethical Issues**

Not applicable.

**References**

1. World Health Organization. Global Health Observatory. https://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf. Accessed November 1, 2020.
2. World Health Organization. Global Health Observatory. https://gco.iarc.fr/tomorrow/home. Accessed November 1, 2020.
3. National Institute of Health, National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/types/. Accessed November 1, 2020.
4. Chidambaram M, Manavalan R, Kathiresan K. Nanotherapeutics to overcome conventional cancer chemotherapy limitations. J Pharm Pharm Sci 2011; 14(1):67-77. doi: 10.18433/j30c7d
5. Li J, Chen F, Cona MM, Feng Y, Himmelreich U, Oyen R, et al. A review on various targeted anticancer therapies. Target Oncol 2012; 7(1):69-85. doi: 10.1007/s11523-012-0212-2
6. Bhullar KS, Lagarón NO, McGowan EM, Parmar I, Jha A, Hubbard BP, et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer 2018;17(1):48. doi: 10.1186/s12953-018-0804-2
7. Herbrink M, Nuijten B, Schellens JH, Beijnen JH. Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer Treat Rev 2015;41(5):412-22. doi: 10.1016/j.
9. Parhi R, Suresh P. Preparation and characterization of solid lipid nanoparticles—a review. *Curr Drug Discov Technol* 2012;9(1):2-16. doi: 10.2174/1570163127930452

10. Moradpour Z, Barghi L. Novel approaches for efficient delivery of tyrosine kinase inhibitors. *J Pharm Pharm Sci* 2015;18(4):527-48. doi: 10.18433/jfps.209891

11. Josephs DH, Fisher DS, Spicer J, Flanagan RJ. Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring. *Ther Drug Monit* 2013;35(5):562-87. doi: 10.1097/FTD.0b013e318292b931

12. Di Gion P, Kanefendt F, Lindauer A, Scheffler M, Doroshenko O, Fuhr U, et al. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyroles. *Clin Pharmacokinet* 2011;50(9):551-603. doi: 10.2165/11593320-000000000-000000

13. Ferguson FM, Gray NS. Kinase inhibitors: the road ahead. *Nat Rev Drug Discov* 2018;17(5):353-77. doi: 10.1038/nrd.2018.21

14. Roskoski RJ Jr. Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update. *Pharmacol Res* 2020;152:104609. doi: 10.1016/j.phrs.2019.104609

15. Asiner J. Overview of the changing paradigm in cancer treatment: oral chemotherapy. *Am J Health Syst Pharm* 2007;64(Suppl 5):S4-7. doi: 10.2146/ajhp070035

16. Rowland A, van Dyk M, Mangoni AA, Miners JO, McKinnon RA, Wiese MD, et al. Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure. *Expert Opin Drug Metab Toxicol* 2017;13(1):31-49. doi: 10.1007/s13292-016-229303

17. Zhu L, Lu Q, Wang S, Wu J, Shi J, Yan T, et al. Oral absorption basics: pathways and physicochemical and biological factors affecting absorption. In: Qiu Y, Chen Y, Zhang GZ, Yu L, Mantri RV, eds. *Developing Solid Oral Dosage Forms*. 2nd ed. Boston: Academic Press; 2017. p. 297-329. doi: 10.1016/b978-0-12-802447-8.00011-x

18. European Medicines Agency (EMA)/Public Assessments Reports (PARs). Available from: https://www.ema.europa.eu/en/.

19. US Food and Drug administration (FDA). Product Label Descriptions). Available from: https://www.fda.gov/.

20. Yu H, Steeghs N, Nijenhuis CM, Schellens JH, Beijnen JH, Huijtert AD. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. *Clin Pharmacokinet* 2014;53(4):305-25. doi: 10.1007/s40262-014-0137-2

21. Kumar S, Bhargava D, Thakkur A, Arora S. Drug carrier systems for solubility enhancement of BCS class II drugs: a critical review. *Crit Rev Ther Drug Carrier Syst* 2013;30(3):217-56. doi: 10.1615/critrevtherdrugcarriersyst.2013005964

22. Dahan A, Miller JM, Amidon GL. Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs. *AAPS J* 2009;11(4):740-6. doi: 10.1208/s12248-009-9144-x

23. Herbrink M, Schellens JH, Beijnen JH, Nuijen B. Inherent formulation issues of kinase inhibitors. *J Control Release* 2016;239:118-27. doi: 10.1016/j.jconrel.2016.08.036

24. US Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review. [https://www. accessdata.fda.gov/scripts/cder/daf/index.cfm](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm)

25. Evans DF, Pyy E, Bramley R, Clark AG, Dyson TJ, Hardcastle JD. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. *Gut* 1988;29(8):1035-41. doi: 10.1136/gut.29.8.1035

26. Yuen KH. The transit of dosage forms through the small intestine. *Int J Pharm* 2010;395(1-2):9-16. doi: 10.1016/j.ijpharm.2010.04.045

27. Budha NR, Frymoyer A, Smelick GS, Jin Y, Yago MR, Dresser MJ, et al. Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? *Clin Pharmacol Ther* 2012;92(2):203-13. doi: 10.1038/cpt.2012.73

28. Devadas VR, Deb PK, Maheshwari R, Sharma P, Tekade RK. Physicochemical, pharmaceutical, and biological considerations in GIT absorption of drugs. In: Tekade RK, ed. *Dosage Form Design Considerations*. Academic Press; 2018. p. 149-78. doi: 10.1016/b978-0-12-814423-7.00005-8

29. Stuurman FE, Nuijen B, Beijnen JH, Schellens JH. Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement. *Clin Pharmacokinet* 2013;52(6):399-414. doi: 10.1007/s40262-013-0040-2

30. Harde H, Das M, Jain S. Solid lipid nanoparticles: an oral bioavailability enhancer vehicle. *Expert Opin Drug Deliv* 2011;8(11):1407-24. doi: 10.1517/17452547.2011.604311

31. Tucker GT. Pharmacokinetic considerations and challenges in oral anticancer drug therapy. *Clin Pharmacol* 2019;11(6):1-14.

32. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv Drug Deliv Rev* 2001;46(1-3):2-26. doi: 10.1016/s0169-409x(00)00129-0

33. Pathak K, Raghuvanshi S. Oral bioavailability: issues and solutions via nanoformulations. *Clin Pharmacokinet* 2015;54(4):325-57. doi: 10.1007/s40262-015-0242-x

34. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. *J Med Chem* 2002;45(12):2615-23. doi: 10.1021/jm020017n

35. Gerber W, Steyn JD, Kotzé AF, Hamman JH. Beneficial pharmacokinetic drug interactions: a tool to improve the bioavailability of poorly permeable drugs. *Pharmaceutics* 2018;10(3):106. doi: 10.3390/pharmaceutics10030106

36. Savla R, Browne J, Plassat V, Wasan KM, Wasan EK. Review and analysis of FDA approved drugs using lipid-based formulations. *Drug Dev Ind Pharm* 2017;43(11):1743-58. doi: 10.1080/03639045.2017.1342654

37. Čepnjak K, Zvonar A, Gašperlin M, Vrečer F. Lipid-based systems as a promising approach for enhancing the bioavailability of poorly water-soluble drugs. *Acta Pharm* 2013;63(4):427-45. doi: 10.2478/aphc-2013-0040

38. Koch KM, Reddy NJ, Cohen RB, Lewis NL, Whitehead B, Mackay K, et al. Effects of food on the relative bioavailability of lapatinib in cancer patients. *J Clin Oncol* 2009;27(8):1191-6. doi: 10.1200/jco.2008.15.3285

39. Ling J, Fettner S, Lum BL, Riekk M, Rakshit A. Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. *Anticancer Drugs* 2008;19(2):209-16. doi: 10.1097/CAD.0b013e328282fd8e

40. Moulby S, Lloret-Linares C, Sellier PO, Sene D, Bergmann JF. Is the clinical relevance of drug-food and drug-herb interactions limited to grapefruit juice and Saint-John’s Wort? *Pharmacol Res* 2017;118:82-92. doi: 10.1016/j.phrs.2016.09.038

41. Keller KL, Franquiz MJ, Duffy AP, Trovato JA. Drug-drug interactions in patients receiving tyrosine kinase inhibitors. *J Clin Oncol* 2018;36(24):110-5. doi: 10.1007/s10967-018-2311

42. US Food and Drug Administration. Datasinib (sprycel) prescribing information (2018). [https://www.accessdata.fda.](https://www.accessdata.fda.gov/).
SLNs for Efficient Oral Delivery of TKIs

Krivniakova M, Skoda J, Neradil J, Chlapek P, Veselska R. Repurposing tyrosine kinase inhibitors to overcome multidrug resistance in cancer: a focus on transporters and lysosomal sequestration. Int J Mol Sci 2020;21(9):3157. doi: 10.3390/ijms21093157

Lin L, Yee SW, Kim RB, Giacomini KM. SLC transporters as therapeutic targets: emerging opportunities. Nat Rev Drug Discov 2015;14(8):534-60. doi: 10.1038/nrd4626

Kato M. Intestinal first-pass metabolism of CYP3A4 substrates. Drug Metab Pharmacokinet 2008;23(1):87-94. doi: 10.2133/dmpk.23.87

Wright WC, Chenge J, Chen T. Structural perspectives of the CYP3A family and their small molecule modulators in drug metabolism. Liver Res 2019;3(3-4):132-42. doi: 10.1016/j.livres.2019.08.001

Kivistö KT, Niemi M, Fromm MF. Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundam Clin Pharmacol 2004;18(6):621-6. doi: 10.1111/j.1472-8206.2004.00291.x

Pathania S, Bhatia R, Baliq S, Singh R, Rawal RK. Drug metabolizing enzymes and their inhibitors' role in cancer resistance. BioMed Pharmacother 2018;105:53-65. doi: 10.1016/j.biopha.2018.05.117

Teo YL, Ho HK, Chan A. Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations. Br J Clin Pharmacol 2015;79(2):241-53. doi: 10.1111/bcp.12496

van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG. Drug-drug interactions with tyrosine-kinase inhibitors: a review. Nanosci Nanotechnol Res 2017;2(3):289-300.

Selleckchem.com website. http://www.selleckchem.com/. Accessed February 18, 2021.

van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol 2014;15(8):e315-26. doi: 10.1016/S1470-4247(13)70579-5

Jr. RR. Blue ridge institute for medical sciences. http://www.brmit.org/PKI/PLKS.htm. Accessed February 18, 2021.

Mishra V, Bansal KK, Verma A, Yadav N, Thakur S, Sudhakar K, et al. Solid lipid nanoparticles: emerging colloidal nano drug delivery systems. Pharmaceuticals 2018;10(4):191. doi: 10.3390/healthcare10040191

Kishawy M, Nasr A. Solid lipid nanoparticles (SLNs) as nano drug delivery carriers: preparation, characterization and application. Int J Appl Pharm 2020;12(1):1-9. doi: 10.22159/ijap.2020v12i1.35312

Ram DT, Debnath S, Babu MN, Nath TC, Thejeswi B. A review on solid lipid nanoparticles. Res J Pharm Technol 2012;5(11):1359-68.

Müller RH, Rühl D, Runge S, Schulze-Forster K, Mehrtens W. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm Res 1997;14(4):458-62. doi: 10.1023/a:1012043315093

Duan Y, Dhar A, Patel C, Khimani M, Neogi S, Sharma P, et al. A brief review on solid lipid nanoparticles: part and parcel of contemporary drug delivery systems. RSC Adv 2020;10(45):26777-91. doi: 10.1039/d0ra03491f

Mehrtens W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2012;64 Suppl:83-101. doi: 10.1016/j.addr.2012.09.021

Wang H, Wang H, Yang H, Wu M, Sun S, Xie B. Improved oral bioavailability and liver targeting of sorafenib solid lipid nanoparticles in rats. AAPS PharmSciTech 2019;20(2):761-8. doi: 10.1186/s12249-017-9091-3

Ahmed MM, Fatima F, Anwer MK, Aldawsari MF, Alsaidan YSM, Alaziz SA, et al. Development and characterization of brigitamin loaded solid lipid nanoparticles: in-vitro cytotoxicity against human carcinoma A549 lung cell lines. Chem Phys Lipids 2020;233:105003. doi: 10.1016/j.chemphyslip.2020.105003

Suvarshaa G, Velmurugan R, Reddy AP. Development and optimization of solid lipid nanoparticle formulation for enhanced solubility of cetirizin using Box–Behnken design. Asian J Pharm 2020;14(1):123-32. doi: 10.22377/ajp.v14i1.3537

Balkhtiar Z, Barar J, Aghnejad A, Saei AA, Nemati E, Ezzati Nazhad Dolatabadi J, et al. Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer. Drug Dev Ind Pharm 2017;43(8):1244-53. doi: 10.1080/03639045.2017.1310233

Sanati N, Taymouri S, Varshojas A, Rostami M, Mirian M. Preparation and evaluation of inhalable dry powder containing glucosamine-conjugated gefitinib SLNs for lung cancer therapy. Drug Dev Ind Pharm 2020;46(8):1265-77. doi: 10.1080/03639045.2020.1788063

Lingayat VJ, Zarekar NS, Shendge RS. Solid lipid nanoparticles: a review. Nanosci Nanotechnol Res 2017;2(2):67-72. doi: 10.12691/nrr-4-2-5

Tekade RK, Maheshwari R, Tekade M, Chougule MB. Solid lipid nanoparticles for targeting and delivery of drugs and genes. In: Mishra V, Kesharwani P, Mohd Amin MCI, Iyer A, eds. Nanotechnology-Based Approaches for Targeting and Delivery of Drugs and Genes. Academic Press; 2017. p. 256-86. doi: 10.1016/b978-0-12-809717-5.00010-5

Üner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine 2007;2(3):289-300.

Satapathy SP, Patro CS. Applications of Solid Lipid Nanoparticle. Indian Journal of natural sciences 2020;10(62):28064-28069.

Wong HL, Bendayan R, Rauth AM, Li Y, Wu Y, Wu YX. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev 2007;59(6):491-504. doi: 10.1016/j.addr.2007.04.008

Bayón-Cordero L, Alkorta I, Arana L. Application of solid lipid nanoparticles to improve the efficiency of anticancer drugs. Nanomaterials (Basel) 2019;9(3):474. doi: 10.3390/ nanom9030474

Hu L, Tang X, Cui F. Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. J Pharm Pharmacol 2004;56(12):1527-35. doi: 10.1211/00223375044959

Vemula VR, Lagishetty V, Lingala S. Solubility enhancement techniques. Int J Pharm Sci Res 2015;6(1):41-51.

Thanki K, Gangwal RP, Sangamwar AT, Jain S. Oral delivery of anticancer drugs: challenges and opportunities. J Control Release 2013;170(1):15-40. doi: 10.1016/j.jconrel.2013.04.020

Salah E, Abouelfetouh MM, Pan Y, Chen D, Xie S. Solid lipid nanoparticles for enhanced oral absorption: a review. Colloids Surf B Biointerfaces 2020;196:111305. doi: 10.1016/j.colsurfb.2020.111305

Wang YJ, Zhang YK, Kathawala RJ, Chen ZS. Repositioning of tyrosine kinase inhibitors as antagonists of ATP-binding cassette transporters in anticancer drug resistance. Cancers (Basel) 2014;6(4):1925-52. doi: 10.3390/cancers6041925

Mei L, Zhang Z, Zhao L, Huang L, Yang X, Tang J, et al. Pharmaceutical nanotechnology for oral delivery of anticancer drugs. Adv Drug Deliv Rev 2013;65(6):880-90. doi: 10.1016/j.addr.2012.11.005

Majidinia M, Mirza-Aghazadeh-Attari M, Rahimi M, Mihanfar A, Karimian A, Safa A, et al. Overcoming multidrug resistance in cancer: Recent progress in nanotechnology and new horizons. J UMBR Life 2020;72(5):855-71. doi: 10.1002/iumb.2215

Reddy RS, Dathar S. Nano drug delivery in oral cancer therapy: an emerging avenue to unveil. J Med Radiol Pathol Surg 2015;1(5):17-22. doi: 10.15713/ims.jmprs.31

Miao J, Du YZ, Yuan H, Zhang XG, Hu FQ. Drug resistance
reversal activity of anticancer drug loaded solid lipid nanoparticles in multi-drug resistant cancer cells. Colloids Surf B Biointerfaces 2013;110:74-80. doi: 10.1016/j.colsurfb.2013.03.037

79. Mazzaferro S, Bouchenal K, Ponchel G. Oral delivery of anticancer drugs I: general considerations. Drug Discov Today 2013;18(1-2):25-34. doi: 10.1016/j.drudis.2012.08.004

80. Zhang Z, Gao F, Jiang S, Ma L, Li Y. Nano-based drug delivery system enhances the oral absorption of lipophilic drugs with extensive presystemic metabolism. Curr Drug Metab 2012;13(8):1110-8. doi: 10.2174/138920012802850100

81. Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev 2016;99(Pt A):28-51. doi: 10.1016/j.addr.2015.09.012

82. Yuan H, Chen CY, Chai GH, Du YZ, Hu FQ. Improved transport and absorption through gastrointestinal tract by PEGylated solid lipid nanoparticles. Mol Pharm 2013;10(5):1865-73. doi: 10.1021/mp300649z

83. Yáñez JA, Wang SW, Knemeyer IW, Wirth MA, Alton KB. Intestinal lymphatic transport for drug delivery. Adv Drug Deliv Rev 2011;63(10-11):923-42. doi: 10.1016/j.addr.2011.05.019

84. Cai S, Yang Q, Bagby TR, Forrest ML. Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles. Adv Drug Deliv Rev 2011;63(10-11):901-8. doi: 10.1016/j.addr.2011.05.017

85. Paliwal R, Rai S, Vaidya B, Khatri K, Goyal AK, Mishra N, et al. Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine 2009;5(2):184-91. doi: 10.1016/j.nano.2008.08.003

86. Campos JR, Severino P, Santini A, Silva AM, Shegokar R, Souto SB, et al. Solid lipid nanoparticles (SLN): prediction of toxicity, metabolism, fate and physicochemical properties. In: Shegokar R, ed. Nanopharmaceuticals. Elsevier; 2020. p. 1-15. doi: 10.1016/b978-0-12-817778-5.00001-4

87. Bahuguna A, Khan I, Bajpai VK, Kang SC. MTT assay to evaluate the cytotoxic potential of a drug. Bangladesh J Pharmcol 2017;12(2):115-8. doi: 10.3329/bjp.v12i2.30892

88. Attama AA, Umeyor CE. The use of solid lipid nanoparticles for sustained drug release. Ther Deliv 2015;6(6):669-84. doi: 10.4155/tde.15.23

89. Gupta B, Poudel BK, Pathak S, Tak JW, Lee HH, Jeong JH, et al. Effects of formulation variables on the particle size and drug encapsulation of imatinib-loaded solid lipid nanoparticles. AAPS PharmSciTech 2016;17(3):652-62. doi: 10.1208/s12249-015-0384-z